February 2012

SPECIAL

Euro BioFairs Compasso

II II II The Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideThe Life Sciences Events GuideII The Life Sciences Events Guide

31_EBSIN1-2_12_Compass_Titel_tg.indd 1 02.02.2012 12:32:52 Uhr

European Biotechnology Foundation | Rue d’Egmont 15 | B-1000 Bruxelles, BelgiqueTel: +32 2 50 08 531 | Fax +32 2 64 92 989 | info@european-biotechnology.org | www.european-biotechnology.net

EuropeanBiotechnology

Net work

Doing the business!

29th March 2012Building Transatlantic Partnerships is supported by ‘Doing the busi-

ness’, an intensive 1 day workshop on the logistics of biotechnology

business in the US. With just 15 places available, the day focuses

beyond the technology, with factors for success, corporate partner-

ing, investment and grants and effective integration into different

market and biotech culture.

Visit www.european-biotechnology.net and click on our events

to find out more and book your place!

Meeting supported by:

30th March | BrusselsJoin the European Biotechnology Network to explore how European biotechnology research can build US partner-ships through the key funding mechanisms open on both sides of the Atlantic. Framework Programme Seven and Ho-rizon 2020 from Europe combine with National Institutes of Health (NIH), Department of Defense (DOD) and the Bill and Melinda Gates Foundation from the US. Academia and in-dustry from the US and Europe can fund partnerships through these programmes and accelerate technology and clinical/market application. The day brings together the Eu-ropean Commission and organisations active in European-US partnerships, from academia, SMEs and pharma, to showcase partnerships and the mechanisms behind them.

In the memory of last year’s inspirational keynote speaker, Ian Bathurst, the meeting supports Medicines for Malaria Venture (MMV) a Swiss-based public-private initiative whose donor, stakeholder and grantee network across the US and Europe is exemplary of the kind of partnership we hope toshowcase.

builDing transatlantic PartnershiPs in biotechnology

Please register now at www.european-biotechnology.net through the event pages.

GrüneckerPatent- und Rechtsanwälte

EBN_EA_links_TransPartnership_210x275.indd 1 02.02.2012 12:45:28 Uhr

Euro|Biotech|NewsNº 1-2 | Volume 11 | 2012 33

Euro Biofairs Compass

Partnering and licence deals will be high on the agenda in March, with two events relevant to business developers in bio-technology and pharmaceutical compa-nies – the euroPLX in Cascais (Portugal), and the BioEurope Spring in Amsterdam (The Netherlands). Both the focussed euro PLX event and the BIO-Europe’s lit-tle brother will raise the curtain on a year in which analysts say the pharmaceutical industry is expected to spend an increas-ing amount of money on external projects

Intro

Half a year of superlative events Welcome to the spring conference season 2012, which offers a series of highlights that could impact your business. Whether you are looking to find a partner for drug development, to translate your products into the clinic or to look for the latest de-velopments in laboratory and bioprocessing equipment, you’ll find all you need to know in this issue of the EuroBiotech Compass, which is now part of EuroBiotech-news – the monthly news journal for the European life sciences sector.

with biotechs. Here is where Europe’s bio-pharmaceutical scene comes face-to-face to negotiate new license agreements.

Trade fairs & conferences

Every six years, two of Europe’s major events for laboratory and biotech equip-ment take place in the same year. In mid-April, the Munich-based Analytica opens its doors to more than 30,000 visitors, who will come to view showcased products from

more than 1,000 exhibiting companies and developers in the lab equipment sector. Updates on technology development will be integrated into the trade fair.

Then in mid-June it will be time to head for ACHEMA – Europe’s largest confer-ence/trade fair for biotechnology, chem-ical engineering and environmental pro-tection. Around 175,000 visitors are ex-pected to attend the event in Frankfurt, where exhibitors show off the latest progress in instrumental analytics, bio-processing and equipment for industrial manufacture. At the associated confer-ence, more than 900 lectures will give vis-itors an update on the latest research and development trends. This time around, special focusses will include bio refineries and the current research on enzymat-ic conversions that are relevant to the emerging idea of a bio-economy.

Another must for drug-discovery ex-perts and users of high-throughput (HT)technologies will be taking place for the second time in Hamburg. After its suc-cessful premiere, the European Lab Auto-m ation Congress will again provide an up-date on progress in liquid handling, HT seq uencing techniques, sample prepa-ration and miniaturisation, along with an exhibition that includes the relevant play-ers in the field.

In July, the Medtech Pharma 2012 con-gress/fair will guide researchers, devel-opers, manufacturers and service pro-viders through the latest developments in pharma and medical technology develop-ment. Additionally, the congress will pro-vide insights into the latest developments in regenerative medicine, imaging, diag-nostics, targeted therapies and drug de-livery devices.

Beyond Europe’s borders

For European companies that want to enter the Asian market, the BioTech 2012 is the place to be. The successor to BioExpo Japan is Asia’s largest drug discovery & life sci-ences event, and will provide the ideal op-portunity to meet relevant industry figures and make business contacts. The structure of BioTech 2012 rests on three pillars: trade show, partnering and the exhibition.� B

From bench to market – biotech events will draw hundreds of thousands of visitors in 2012.

© D

euts

che

Mes

se A

G

33_EBSIN1-2_12_Special_Intro_tg.indd 33 03.02.2012 11:29:46 Uhr

34 Euro|Biotech|News Nº 1-2 | Volume 11 | 2012

Euro Biofairs Compass

In contrast to other partnering conferenc-es, euroPLX events focus just on business events, leaving out presentations, lectures and exhibitions. Moreover, admittance is reserved to life science executives who are in charge of their companies’ business development. euroPLX will accept service companies only provided that they “touch” the real product - at least its dossier or li-cense. Delegates from consulting compa-nies, associations, governments, or staff-

GreetinG

Efficient and valuableeuroPL X meet-ings are the ideal place for pharma deals, attended by industry exec-utives in charge of business devel-opment, commer-cial operations, marketing, and brokers or consultants with clear mandates. No other pharma or bio tech partnering con-ference worldwide has been held as often as euro PLX, with 47 events between 1995 and 2011. Some impressions from former conference delegates: “The best value for money venue”, “most efficient and valuable”, “highly effective and pleasant”, “excellent platform”, “an indispensable tool”, “tough and intense”, “highly focussed”, “smooth organisation”, “always professional and user-friendly” – these are just some of the euroPLX attributes, as publicly stat-ed by business development executives. It is therefore not surprising that many companies have attended more than 30 euroPLX meetings since 1995! For us, re-turning customers are the best evidence of delivered benefit. See you at our three euroPLX conferences in 2012! See you in Portugal!

Dr. norbert rau RauCon Business DevelopmentCo-initiator of euroPLX

eUrO-PLX 48 LisbOn

Pure partneringDifferent from other matchmaking events in the pharma and biotech business, euroPLX conferences stand out because they are focused on the key to successful partnering: the face-to-face meeting. euroPLX conferences can rely on unmatched experience, with nearly 50 events since their initiation 17 years ago. A large number of pharma companies are regular guests at euroPLX meetings.

ing companies are not admitted. At any partnering conference, the probability of a pre-scheduled appointment decreases with increasing size of the event, owing to the limited number of available half-hour meeting slots. For this reason euroPLX meetings deliberately limit the number of delegates admitted, but are more frequent than just once a year. The markedly differ-ent conference design results in an aston-ishing 23 to 25 pre-scheduled face-to-face meetings per company, a total of close to 10,000 in 2011. This makes euroPLX more productive than most, which offer just a handful of appointments. The more face-to-face meetings, the more opportunities generated. The feedback from regular eu-roPLX attendees indicates one signed deal for every 10 to 12 appointments, signed within anything between six weeks and three years after the initial discussions. That’s why many companies have had del-egates at more than 30 euroPLX meetings. Customers who return repeatedly are a distinguishing mark of euro PLX. To regis-ter for euroPLX and for more information please visit www.europlx.com� B

DeLeGAtesMore than 140 pharma companies in Europe are already registered.

VenUeFive-star Hotel Miragem in Cascais near Lisbon will host the event.

timeLine Registration deadline is 16 Februarywww.europlx.com

› QUick fActs

5 – 6 march, 2012Hotel cascais miragemcascais/ Portugal

34_EBSIN1-2_12_special_PLX_pg.indd 34 02.02.2012 12:35:11 Uhr

48

49

4150

51

euroPLX 48 Lisbon (Portugal)

March 5 + 6, 2012

euroPLX 50 Sorrento (Italy)

Novem

ber 5 + 6, 2012

euroPLX 51 Limassol (Cyprus)

March 4 + 5, 2013

Continuous Business Developm

ent

Since 1995. Made in

Europe for the World.

euroPLX 49 Istanbul (Turkey)

June 4 + 5, 2012

Kurfürstenstr. 1A69234 Dielheim, Germanyph. ++49 (6222) 9807-0meetyou@europlx.com

Dynamic Partnering Focus

Partnering from innovative to generic, from early stage candidates to approved, prescription or OTC drugs.

Registrants determine the dynamically evolving focus of each euroPLX Meeting. Displayed* and updated hourly on

www.europlx.com

* as soon as sufficient data are submitted

Continuity and Follow-Up

On average, euroPLX delivers 23 to 24 pre-scheduled business negotiations per company. And results.

Three times a year. Year after year. Productive continuity and shorter time to market.

The Leading OriginalPlatform for Continuity in Life Science and Pharma Business Development: Meet You @ euroPLX!

Productive Partnering for Pharma Deals

e49-50EuroBioFairs.indd 1 26.01.12 11:3335_EBSIN1-2_12_Raucon.indd 1 01.02.2012 17:26:30 Uhr

36 Euro|Biotech|News Nº 1-2 | Volume 11 | 2012

Euro Biofairs Compass

19 – 21 March, 2012Amsterdam RAI Convention Center Amsterdam/The Netherlands

For biotechs, 2012 is going to be a good year when it comes to finding a phar-ma partner. While the value of acquisi-tions announced by Europe’s ten largest pharma companies plunged to a1.65bn in 2011 from a33.5bn the year before, pharma patents worth a16.5bn are set to expire, according to market analyses published by Bloomberg. With growing pressure from generics, big pharma’s

L i fe science indus-tr y dealmakers and decisionmakers will make Amsterdam the center of partnering at the 6th annual BIO-Eu-rope Spring®. With over

BIo-EuRopE SpRINg

A good year for deals BIo-Europe Spring®, the counterpart to EBD group’s flagship partnering conference BIo-Europe®, will bring bio-pharma executives and investors to Amsterdam in early 2012. At the heart of the meeting once again is partneringoNE®, a web-based system for finding development partners or investors. In addition to productive partnering, BIo-Europe Spring also offers insightful workshops and panels, company presen-tations and a lively exhibition.

HIgHlIgHTSMajor Partnering Event for Pharma, Biotech and Investment ExecutivesCompany Presentations, Discussion Panels, Exhibition

VENuE & INfoRMATIoNAmsterdam RAI Convention Center Europaplein 22, 1078 GZ Amsterdam

www.ebdgroup.com/bes

› QuICk fACTS

interest in licensing innovative drug pro-grammes – even in early-stage develop-ment – will grow. On 6 February, online partnering for the BIO-Europe Spring 2012 event being held on 19-21 March in Amsterdam will open.

This year, over 10,000 one-to-one meet-ings will be held during the three-day con-ference. 70 international exhibitors and more than 45 countries will showcase

their offerings across the life sciences value chain. In addition, more than 2,000 delegates will have the opportunity to view 120 company presentations and at-tend 17 workshops and panels, where in-dustry leaders will speak about the lat-est trends.

In Amsterdam, the impact of new tech-nologies on personalised oncology and the trend towards developing targeted niche busters will be high on the list of topics, along with analyses of current deals, biotech business models for faster returns and early-stage financing.

At the conclusion of BIO-Europe Spring, delegates can continue to nurture the con-nections made at the event with partner-ing360®. Launched last autumn at the BIO-Europe in Düsseldorf, partnering360 enables delegates to continue networking and move deals forward in-between part-nering events, ensuring a highly productive and efficient partnering process. To regis-ter for BIO-Europe Spring and for more in-formation see www.ebdgroup.com/bes� B

gREETINg

A perfect place to find partners

10,000 partnering meetings, the confer-ence is one of the most productive part-nering events in the world. In addition to productive partnering, the BIO-Europe Spring also offers workshops and pan-els, company presentations, and a dy-namic exhibition that helps you to cre-ate opportunities to power-network with your peers. I look forward to seeing you in Amsterdam!

Carola SchroppPresidentEBD Group, Inc.

36_EBSIN1-2_12_special_BES_tg.indd 36 03.02.2012 11:30:44 Uhr

JANUARY 7–9, 2013SAN FRANCISCO, CA, USA

SEPTEMBER 19–21, 2012BOSTON, MA, USA

MARCH 19–21, 2012AMSTERDAM, THE NETHERLANDS

MAY 23–24, 2012SUZHOU, CHINA

MAY 31–JUNE 1, 2012GRENOBLE, FRANCE

NOVEMBER 12–14, 2012HAMBURG, GERMANY

Join the most productive partnering platform in the life science industry

BIOPHARM AMERICA™

BIO-EUROPE SPRING®

BIO-EUROPE BIOTECH SHOWCASE™

CHINABIO®

PARTNERING FORUM

EUROMEDTECH™

Co-producers

Producer

Supported by

Producer

Co-producers

Producer

Hosted by

www.ebdgroup.com Partnerships start here

San

Fran

cisc

o im

age

© S

an F

ranc

isco

Con

vent

ion

& Vi

sito

rs B

urea

u ph

oto

by K

. Jam

es

BES12 097 Kombi 210x275.indd 1 18.01.12 21:5137_EBSIN1-2_12_EBD.indd 1 01.02.2012 17:12:18 Uhr

38 Euro|Biotech|News Nº 1-2 | Volume 11 | 2012

Euro Biofairs Compass

The fair kicks off with a delightful shiver. Germany’s best-known criminal bio log-ist and specialist for forensic entomology, Mark Benecke, will give a presentation at the Biotech Forum on the first day demon-strating how the latest DNA analysis tech-niques can help catch murderers. Anyone who has drawn blood and fancies a hands-

GreetinG

A comprehensive overview in 5 hallsDear readers,

we look forward to welcoming you to Munich for the 23rd Analytica, the In-ternational Trade Fair for Laboratory Technology, Analysis and Biot echnology from 17–20 April, 2012. Leading manufac-turers from around the world with exhib-its in five halls will give visitors a compact market overview of all the latest labora-tory products and equipment. As a special highlight, for the first time ever there will be three completely equipped laboratories featuring, among other things, live demonstrations on the topics of forensics, clinical diag nostics as well as food and water analysis on each day of the fair. Thanks to the Conference and a prac-tice-oriented supporting programme, Analytica again features an extensive range of events in 2012. And for anyone specially interested in the dynamic mar-kets in the Asian region, we have expand-ed our Analytica family: With Analytica China in 2012 and Analytica Vietnam and Analytica Anacon India in 2013, you won’t miss out on any future opportunities. But first things first: Welcome in Munich!

Susanne GrödlExhibition Director Analytica

analytica

Analysing successFor more than four decades, analytica has been the international fair for state-of-the-art laboratory technology and pioneering biotechnology. no other trade fair in the world covers lab matters in industry and science in such breadth and depth, and on such a scale. the last edition of the biennial event in 2010 attracted near-ly 33,000 visitors from 120 countries, while more than 1,000 companies from 37 countries confirmed analytica’s standing as the leading trade fair for the lab tech industry. this year’s edition will try to attract even more exhibitors and visitors to springtime Bavaria.

on approach to real lab work will love the Live Labs. For the first time, Analytica will feature three completely equipped labo-ratories with live demonstrations daily: Forensics & Clinical Diagnostics, Plastics Analysis and Food & Water Analysis. Live Labs aside, it’s no surprise that the ba-sic concept that has served Analytica so well over the years is remaining the same. Three main topics are presented in five halls: Analysis & Quality Control, Biotech-nology / Life Sciences / Diagnostics, and Laboratory Technology. Registered com-panies include a number of heavyweights such as Eppendorf, Fisher Scientific, GE Healthcare, Merck Millipore and Thermo Scientific. The industry itself is optimistic: “I assume that it will continue its growth trend of the past few years again in 2012,” says Mathis Kuchejda of the industry or-ganization Spectaris. He may be right. In autumn 2011, German manufacturers in the sector expected sales to increase by an average of 6% in 2011 alone.� B

HiGHliGHtS Live Labs Mark Benecke: Forensic entomologyConference & ForumsJob & Finance Day

MUnicHDon’t forget to eat “Weisswurst” and drink “Weizen” beer.

www.analytica.de

› QUick FactS

17 – 20 april, 2012neue Messe MünchenMunich /Germany

38_EBSIN1-2_12_special_analytica_cm.indd 38 03.02.2012 11:31:20 Uhr

AWS-BOB_Anzeige_210x275_v1.indd 1 07.12.11 10:5139_EBSIN1-2_12_BOB.indd 1 01.02.2012 17:12:49 Uhr

40 Euro|Biotech|News Nº 1-2 | Volume 11 | 2012

Euro Biofairs Compass

BIO tech is organised by one of the largest global event companies. Reed Exhibitions is responsible for 500 events in 39 coun-tries. In 2011, Reed brought together six million participants from the Americas, Europe, the Middle East and Asia Pacific. The subsidiary in Japan is the leading trade

GreetinG

A unique chance to network

B I O te c h 2 012 , Asia’s largest BIO event, opens its gates in Tokyo on 25 April 2012. The conference and ex-hibition have been reborn from the

International Bio Forum & Bio Expo Ja-pan. With a more international and more substantial business platform, the 2012 show is expected to gather 650 exhib-itors, 300 academic presenters and 28,000 visitors from all over the world. This unique opportunity provides an ide-al platform for presenting the latest de-velopments, innovations, research and products. With its three pillars – the exhibition, the forum with 400 sessions and the part-nering with 5,000 participants – BIO tech 2012 is an event that will provide an all-inclusive experience for any profession-al involved in drug discovery and the life sciences. I’m sure your stay in Tokyo will give you plenty of oppor tunities to en-hance your network and prepare for the market challenges that lie ahead. Welcome to BIO tech 2012!

tad ishizumi Regional President Asia North, Reed Exhibitions

BiO tech 2012

Asia’s life science hubBiO tech, the international Biotechnology exhibition & conference, is both brand new and well-established. the event is the successor to BiO expo Japan, which has gained a reputation as the main venue for life sciences in the Asian exhibition tour. the first edition of BiO tech retains the strengths of its predecessor; it is Asia’s largest drug discovery & life science event, where experts from science and industry mingle and present cutting-edge research and new products. But along with the continuity, there have been some changes as well. For the first time, the event will be held in April, not in June. the organisers are also enhancing the international orientation and strength-ening the partnering.

event organiser in the country. With BIO tech going strong in its revamped 11th edi-tion, the event has become the biggest life sciences meeting in the whole of Asia, and is still expanding fast. In 2012, more than 650 exhibitors are expected, a significant increase compared to last year (510). The growth of BIO tech mirrors the aston-ishing development of the entire Asian life sciences sector in recent years. By estab-lishing itself in several key niche markets, the Asian biotech and pharma industries have thrived in the global biopharma-ceutical market. To cover all relevant as-pects of the sector, BIO tech 2012 consists of three distinct elements: an exhibition covering biomarkers, biopharmaceuti-cals, bioprocessing and bioimaging as well as lab materials, a three-day con-ference where recent Asian bio-pharma trends are discussed, and a forum with over 200 participants from universities, institutes and the world of business.� B

numBers650+ exhibitors28,000+ visitors300+ sessions/seminars hiGhliGht FOrumHundreds of researchers from busi-ness and academia mingle to ex-change insights and foster relations.

http://www.bio-t.jp/en/

› Quick FActs

25 – 27 April, 2012tokyo Big sighttokyo /Japan

40_EBSIN1-2_12_special_biotech2012.indd 40 03.02.2012 11:31:47 Uhr

www.permedicon.com

Supported by: Organized by:

The International Event for Personalized MedicineInterdisciplinary Congress | Trade Exhibition | Projects

Cologne, 19–20 June 2012

“… It was therefore high time that a dialogue-oriented platform like PerMediCon was introduced. (…) This ultimately leads to a better understanding of personalized medicine and all the possibilities it offers.”

Dr. Hagen Pfundner, CEO of Roche Pharma AG and CEO of vfa

“Personalized medicine is no longer some vague vision; it has become a reality. (…) PerMediCon can promote the sharing of expert knowledge and constructive dialogue by all relevant parties involved and is thus of primary importance for the further development of personalized medicine.”

Peer M. Schatz, CEO QIAGEN N.V.

“There is no doubt that personalized medicine is coming. (…) The only question remaining is how fast it will happen.”

Ph. D. Edward Abrahams, President Personalized Medicine Coalition Washington (USA)

PerMediCon: the cross-sector dialogue and networking platform for the complex issue of personalized medicine.

Experts about PerMediCon:

Be part of the next event, which will take place from 19 to 20 June 2012 in Cologne!

For more information please visit www.permedicon.com

PM12_AZ_BioTechnologyNews_210x275mm_GB.indd 1 26.01.12 12:1441_EBSIN1-2_12_Permedicon.indd 1 01.02.2012 17:13:34 Uhr

42 Euro|Biotech|News

Euro Biofairs CompassNº 1-2 | Volume 11 | 2012

Since 1999, Select Biosciences has gained a reputation in consulting biomedical en-terprises. The organisation of conferences in this business area has also always been an important pillar. Starting last year, Se-lect Biosciences wrapped some of its small-er congresses into one integral event: the Euro pean Laboratory Automation (ELA). And

GreetinG

Fostering talks and collaborations

Select Biosciences is delighted to announce that European L ab Automation 2012 will open its gates on 30 May. 2012 will see ELA evolve into an eight-track congress offer-

european Lab automation 2012

Automated success the european Laboratory automation (eLa) event aims to highlight and show-case the latest in automated instruments and workflows. Last year the mélange of informative and topical presentations attracted more than 1,500 participants. Ken browne, director of the organising company Select biosciences, expects this number to rise to well over 2,000. but eLa is more than just a congress. it also fea-tures exhibitions and training courses focused on automated techniques, equip-ment and applications.

of technological innovation, and the rate of change in the field is breathtaking. The or-ganisers are following up on last year’s event structure, combining scientific talks with ex-hibitions of up-to-date-technologies in so-called congress streams. Senior Director Allan M. Ferguson from Merck Healthcare, for example, will share his experiences as the keynote speaker of the “Informatics for Auto mation” track. The stream “Drug Dis-covery Automation” will be spearheaded by Anthony Davies from Trinity College in Dublin. All in all, eight different congress streams are presented at the ELA 2012. Among them: “Nano- and Micro fluidics”, “Biobanking”, “Next-Gen Sequencing Auto-mation” and “Liquid Handling and Robotics”. Like the inaugural event, this year’s follow-up will also take place in the historic city of Hamburg. If your schedule allows you to stay a bit longer, you should consider taking part in one of the seven different training cours-es offered around 29 May. Registrations are accepted via the ELA-website. B

numberS150 exhibitors, 2,000 visitors150 sessions/seminars

HiGHLiGHt ForumAll aspects of lab automation acces-sible under one roof. Combination of scientific talks, vendor exhibitions and training courses.

http://selectbiosciences.com/conferences/ELA2012

› QuicK FactS

30 – 31 may, 2012ccH congress centre Hamburg20355 Hamburg / Germany

ing over 150 scientific presentations on automation and its specific application ar-eas within life science. With an expected attendance of over 2,000 and with more than 150 equipment vendors and sup-porting companies, we hope to provide life science researchers and profession-als with an unparalleled opportunity to foster technological discussions and sci-entific collaboration. We look forward to welcoming you in Hamburg!

Ken browne Director of Select Biosciences Event Organiser

in the same manner that lab automation saves time and multiplies capacities, ELA makes life easier and more effective for vis-iting industry representatives, scientists and decision makers. In its second year of exist-ence, ELA has already filled the the long-felt void of a pan-European Automation event. Lab automation is a product and a driver

42_EBSIN1-2_12_special_ELA_ml.indd 42 03.02.2012 11:32:18 Uhr

E enquiries@selectbiosciences.com P +44 (0)1787 315110 Woodview, Bull Lane, SUDBURY, CO10 0FD, UK

SelectBiosciences.com

HAMBURGGERMANY30 TO 31 MAY

2012

Welcome to our European Lab Automation congress and exhibition, Europe’s largest event dedicated to automation within life science.

Offering over 150 scientific presentations across 8 different conference streams linked with an exhibition containing more than 150 equipment vendors, ELA aims to highlight and showcase the latest in automated instruments and workflows.

Life science researchers and professionals are presented with an unparalleled opportunity to foster technological discussions and scientific collaboration.

Visit www.EuroLabAutomation.com

• Biobanking - Preparation, Storage and Analysis

• Drug Discovery Automation - Chemistry Automation & Compound Management

• Drug Discovery Automation - HCS & Cell Based Assays

• Informatics for Automation

Conference Streams• Liquid Handling & Robotics

• Nano & Microfluidics

• Next-Gen Sequencing Automation

• Separation & Detection

Readers of ‘European Biotechnology News’ receive a 10% discount on their registration fee

Academics please use coupon code 17263

Industry delegates please use coupon code 54344

Low cost exhibition only passes are also available

ELA A4 European Biotechnology News ad.indd 1 30/01/2012 15:3143_EBSIN1-2_12_SelectBiosciences.indd 1 01.02.2012 17:14:09 Uhr

44 Euro|Biotech|News Nº 1-2 | Volume 11 | 2012

Euro Biofairs Compass

18 – 22 June, 2012Messe FrankfurtFrankfurt / Germany

ACHEMA’s portfolio is large: from lab-oratory and analytical techniques over pumps, compressors, valves and fittings to pharma ceutical, packaging and stor-age techniques and many more areas. All of these topics are of interest for the bio-economy. In its 30th edition, the triannual event will once more be the place to be for executives in the fields of chemical engi-neering, biotechnology and related fields.

Five days with more than 3,800 exhibitors and 175,000 visitors from all over the world in buzzing exhibition halls, in-depth discus-sion in 900 lectures, new

AcheMA 2012

Trendsetting summitThe AcheMA is the top international meeting point for decisionmakers and experts from the fields of chemical engineering, biotechnology and environmental protec-tion. This year’s event will  focus on  issues relating  to  the energy revolution and shifts in the raw material base. For the first time, AcheMA is also launching a Part-nering scheme to help an anticipated 175,000 visitors and exhibitors pinpoint suit-able contacts.

ProFile3,800 exhibitors from 50 countries175,000 attendees from 100 countries30,000 executives140,000 m² net exhibition space

hiGhliGhTsBiobasedWorld at ACHEMABIOCHEM Accelerator Forum

www.achema.de

› Quick FAcTs

The fair will provide a showcase for new biotechnological processes in the man-ufacture of valuable compounds, as well as for smart ideas on how to integrate re-newable resources into existing produc-tion cycles. The shift in the raw material base in the bioeconomy will be adressed in “BiobasedWorld at ACHEMA”. It offers the unique chance for established indus-try players and new market entrants – as

well as scientists and investors – to meet in one place and discuss state-of-the-art technologies and products. With this new concept, ACHEMA has acknowledged the fact that biotechnology and renewables now play a part in all areas of process in-dustries. Besides scientific and technical questions, the spotlight will be on market-ready concepts. With the BIOCHEM Accel-erator Forum, ACHEMA offers an opportu-nity to network with different stakeholders in the biobased community. The Forum combines technology transfer, partnering and venture capital events in a single lo-cation. A Business Plan Competition and a series of workshops focusing particularly on business models and SMEs round off a programme that targets not only scientists and entrepreneurs, but also investors and funding organisations. Along with the exhi-bition, the ACHEMA’s second cornerstone is the Congress, where more than 900 lec-tures and up to 27,000 participants will dis-cuss novel biocatalysts, innovative bioproc-esses, biorefineries and other topics.� B

GreeTinG

2012 is an ACHEMA year!

contacts, exciting ideas… more than any of its predecessors, ACHEMA 2012 will be the global meeting point for the bio-eco-nomy. BiobasedWorld at ACHEMA, an in-tegral part of the event, makes the bio-economy visible throughout the exhibition and the congress – accompanied by an BIOCHEM Accelerator Forum, Technology Transfer Days, Partnering and much more. Welcome to ACHEMA 2012!

kurt WagemannExecutive Director DECHEMA e.V.

44_EBSIN1-2_12_special_achema_bk.indd 44 02.02.2012 12:39:07 Uhr

| Customised GMP facilities| Customised process systems| High efficient processes | Cost-optimised production | Optimised plant availability

www.pi.mwgroup.net

We look forward to seeing you. Hall 9.1 Stand B3

18 - 22 June 2012, Frankfurt am Main, Germany

M+W Process Industries GmbH A Company of the M+W Group (HQ)Lotterbergstr. 3070499 Stuttgart, Germany

45_EBSIN1-2_12_M-W.indd 1 01.02.2012 17:14:44 Uhr

46 Euro|Biotech|News

Euro Biofairs CompassNº 1-2 | Volume 11 | 2012

MedTech Pharma 2012 will again be a meeting point to make relevant contact with executives from science and com-panies in the med-tech and pharma sec-tors. For the third time since its start in 2008, the biennial congress-fair will provide insights into translational R&D in the pharmaceutical and med-tech branches.

The focus of this year’s scientific pro-gramme will be high-level lectures on intelligent biomaterials for use in re-

GreetinG

Networks and networking In July you are wel-come to join the in-ternational con-g r e s s M e d Te c h Phar ma 2012 in Nuremberg, Ger-many – one of the mos t impor t ant events for the healthcare sector in Eu-rope. As in 2008 and 2010, we expect around 1,000 participants and more than 100 exhibitors to attend the congress. In three parallel sessions, innovations in pharma, biotech and medtech-related topics will be presented and discussed, including trends in diagnostics, point-of-care systems for near-patient test-ing, new approaches and molecules for targeted therapy, or new materials for regenerative medicine. In a scientific poster exhibition, the latest research re-sults reviewed by an independent com-mittee will be presented in the context of MedTech Pharma 2012. In addition, the congress is being used as a platform for a research symposium of the BMBF, and as an exchange network for three active leading edge clusters in the health sec-tor. Join us at the congress!

Dr. thomas FeiglCEO Forum MedTech PharmaSenior scientific officer of Bayern Innovativ GmbH

Forum meDtech Pharma

Healthcare at heart the latest breakthroughs in medtech and Pharma will be on the agenda of medtech Pharma 2012 in nuremberg, Germany. every two years, the international congress attracts more than 1,000 researchers, developers, manufacturers, suppliers, serv-ice providers and clinical users from the medical and pharmaceutical sectors.

generative medicine, advances in mo-lecular imaging, and applications in MIC & Endoscopy. Three of the German top clusters in medtech will present their results. Additionally, there will be a research symposium from the German Research Ministry (BMBF) with sessions under the headings BioTransporter, MoBi Tech, and Bio Disposables.

Internationally renowned speakers at MedTech Pharma will also give an over-view of the latest achievements in diag-nostics, targeted therapies, new drug delivery vehicles and smart medical de-vices. A plenary session with top-class experts from clinics, research and in-dustry focuses on efficiency in health-care.

Just as in previous years, the interna-tional conference will be accompanied by a large exhibition. About 100 firms and research networks will be on hand to showcase research results, products and services. A state reception at the Kaiser-burg castle on 4 July will be the highlight of the social programme. To register for MedTech Pharma and for more informa-tion visit www.medtech-pharma.de.� B

1,000 delegates (2010: 15 countries)60 lectures in three sessions 100 exhibitors

hiGhliGhtsSymposium Medi-WINGState reception at Kaiserburg castleJob marketInternational delegations

www.medtech-pharma.de

› Quick Facts

04 – 05 July, 2012ncc ostnuremberg / Germany

46_EBSIN1-2_12_special_medtechpharma_tg.indd 46 02.02.2012 12:40:32 Uhr